Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2005

View Archived Issues

Kynurenine 3-monooxygenase: a therapeutic target for Huntington disease

ZK-EPO active against bone metastases in breast cancer

Promising results reported with a lingual spray formulation of alprazolam

Data from the HERA study support the use of Herceptin in early breast cancer

Updated survival data reported from phase I study of IL13-PE38QQR

Phase I gene therapy study for Parkinson's nears completion

ImmuFact IMP-321 enters phase I/II trials

Elixir licenses growth hormone secretagogue from BMS

GSK will not negotiate HER-2 Protein AutoVac vaccine deal

Seattle Genetics and MedImmune form antibody-drug conjugate collaboration

Semafore presents new in vivo data on SF-1126

Model proposed to explain the species-specific effects of SB-497115

Cranberry juice constituents display antiinfluenza potential

EP-2306 and EP-2302 demonstrate lipid-lowering potential in vitro

Update on the efficacy of rosuvastatin in hypercholesterolemia

Triglyceride levels have no effect on the benefits of rimonabant in overweight/obese patients

A drospirenone/estradiol combination decreases blood pressure in high-risk hypertensive women

Prous Science presents key webcast coverage of the 96th Annual Meeting of the AACR

FDA approval for Byetta

Zostavax BLA submission

Celera Genomics submits IND for CRA-024781

Supplemental NDA filed for Tarceva in pancreatic cancer

Fatty acids improve visual function in infants

Novel antiinfective agents claimed in recent patent literature

New treatments for hepatitis disclosed by Genelabs and Enanta

Recent patents describe new treatments for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...